A company discussed on No Priors: AI, Machine Learning, Tech, & Startups.

Powering AI-Driven Drug Discovery with President of Isomorphic Labs Max Jaderberg
Nov 12, 2026 · 39:16
Isomorphic Labs president Max Jaderberg tells Elad Gil that drug discovery must move from empirical trial and error onto computers, using predictive AI models that reach experimental accuracy. AlphaFold was the first proof deep learning could generalize in biology, prompting Isomorphic's 2021 founding. He blames the empirical process for drugs costing $1.5 billion over 15 years with flat approvals, and clinic failures after rat toxicity tests prove only ~30% predictive. Isomorphic generates proprietary data, builds its drug design engine in-house, and focuses on oncology and immunology while partnering with pharma. He argues precise molecule engineering unlocks multidrug cocktails modulating whole pathways and expects predictive disease biology to step-change within five years.

Re-Founding Incumbents for the AI Era with Sequence Holdings Co-Founder and CEO Michael Lee
Sep 24, 2026 · 42:45
Sequence Holdings CEO Michael Lee tells Sarah Guo why incumbents, not startups, should lead AI transformation, and explains the $7.7 billion take-private of insurance broker Baldwin with the Dell Family Office. Lee argues enterprises can't recruit frontier engineering talent, can't trust incrementalist vendors, and can't buy software that hardens today's workflows—so Sequence buys incumbents and refounds them, one deal per year. He describes Atlas, Sequence's reusable platform of data ontology, agent building, and orchestration, and why brokerage economics resist startups. At BankSouth, underwriting time fell 94% in six months and loan closings dropped from 30 days to 11, letting volumes double. Lee closes with lessons from Apollo and Lone Pine: back exceptional people in big markets.

Chasing Trillion-Dollar Companies, Founder Ambition, Token Budgets, & Regulatory Capture
Aug 6, 2026 · 39:30
Sarah Guo and Elad Gil debate trillion-dollar company prospects, arguing that after Anthropic, OpenAI, and SpaceX hit that mark in five years, few more will repeat the pace; they see many hundred-billion-dollar opportunities. They urge founders not to retreat to niche markets out of fear of AI labs, and advise most to consider selling in a 12-to-18-month window if they aren't capturing value as costs fall. On compute, they frame token budgets as scarce, needing return-on-invested-tokens thinking. They assess lab belief that coding is solved within six months and light RSI by end of next year, while noting 18-month forecasts have repeatedly missed. Finally, they warn California's billionaire tax and exit-tax plans push founders to Texas, and that overcorrecting on AI safety risks repeating the regulatory capture that stalled nuclear power.

Building an Autonomous Enterprise for Real-World Services with Netic Founder Melisa Tokmak
Jul 31, 2026 · 34:30
Melisa Tokmak, founder and CEO of Netic, tells Elad Gil how Netic's autonomous AI platform acts as an intermediary for essential services like HVAC, pet care, and roofing, with over 70% of customers now AI-first. She explains why she built a product company rather than an AI roll-up, and how selling to 'slow' industries is easier than assumed—they're value-focused and tech-forward. Big labs aren't threats due to focus and last-mile orchestration; robotics is decades away for these jobs. She screens for agency by asking candidates the hardest thing they've done, and sees private equity now demanding measurable ROI. Her five-year vision is an 'autonomous enterprise' where AI handles everything except physical labor; she is most excited about AI's impact on education and expanding agency.
Powered by PodHood